Do fluoroquinolones lower the seizure threshold and increase the risk of seizures, particularly in patients with pre‑existing central nervous system disorders, epilepsy, renal impairment, or concurrent CNS‑active medications?

Fluoroquinolones and Seizure Risk

Fluoroquinolones do carry a recognized risk of seizures, but the absolute risk is low (approximately 1 in 5,400 treatment days), and this risk should be carefully weighed against the severity of infection, particularly in patients with pre-existing CNS disorders, epilepsy, renal impairment, or concurrent use of seizure-threshold-lowering medications. 1

Magnitude of Seizure Risk

The actual incidence of fluoroquinolone-associated seizures is quite low in clinical practice:

• Hospitalized patients treated with fluoroquinolones experienced seizures at a rate of 0.06% (1 per 5,422 treatment days) 2
• When compared directly to macrolide antibiotics using propensity score matching, fluoroquinolones showed no statistically significant increased risk (OR 1.44,95% CI 0.59-3.5, P=0.42) 2
• A large comparative study found a modest increased hazard ratio of 1.08 (95% CI 1.05-1.11) for CNS dysfunction with fluoroquinolones versus comparator antibiotics 3

Importantly, a 2016 self-controlled case series study found that the increased seizure risk occurred primarily in the pre-fluoroquinolone period, suggesting that the underlying infection requiring treatment—rather than the drug itself—may be the primary driver of seizure risk 4

High-Risk Patient Populations

Certain patients face substantially elevated seizure risk when prescribed fluoroquinolones:

CNS Disorders and Epilepsy

• Patients with pre-existing CNS disorders require caution when prescribed moxifloxacin, as seizures are listed as a serious adverse effect 1
• Evidence regarding symptomatic seizures from fluoroquinolones is predominantly from case reports in patients with mental disorders, prior seizures, or brain lesions 5

Renal Impairment

• Most fluoroquinolone-associated seizure reports involve patients with renal dysfunction 5
• Dose reduction by 50% is recommended when GFR <15 mL/min/1.73 m² 6
• Renal impairment increases drug accumulation and CNS penetration 7

Geriatric Patients

• CNS effects of fluoroquinolones—including agitation, insomnia, anxiety, dizziness, confusion, and weakness—are potentiated in older adults 8
• The risk for dizziness is higher with levofloxacin than ciprofloxacin 8
• Geriatric patients are more susceptible to fluoroquinolone-induced seizures due to age-related pharmacokinetic changes and polypharmacy 9

Drug Interactions That Lower Seizure Threshold

• NSAIDs combined with fluoroquinolones create a possible increased risk of convulsions 1
• Theophylline co-administration increases convulsion risk; theophylline dose should be reduced and levels monitored 1
• Antiepileptic drugs like carbamazepine may decrease fluoroquinolone absorption 8

Mechanisms of Seizure Induction

Fluoroquinolones lower seizure threshold through multiple pathways:

• Direct and indirect GABA antagonism, leading to decreased inhibitory neurotransmission 7
• Inhibition of GABA synthesis 7
• NMDA receptor agonistic activity, increasing excitatory neurotransmission 7
• Blockage of myoneural presynaptic acetylcholine release 7
• Mitochondrial dysfunction and oxidative stress from neurotoxic radical generation 7

Variability Within the Fluoroquinolone Class

Not all fluoroquinolones carry equal neurological risk:

• Ciprofloxacin has the most case reports for seizures, particularly in patients with renal dysfunction 5
• Moxifloxacin is associated with twice the risk for arrhythmia compared to ciprofloxacin and levofloxacin, though CNS effects are documented across the class 8
• Fourth-generation fluoroquinolones and unsubstituted penicillins show higher seizure associations than other antibiotics 5

Clinical Management Recommendations

When fluoroquinolones must be used in high-risk patients:

• Avoid fluoroquinolones entirely in patients with known epilepsy or active CNS pathology unless no alternative exists 1, 10
• Monitor closely for altered mental status, as most cephalosporin-associated seizures are nonconvulsive; consider continuous EEG in patients with altered consciousness 5
• Reduce dose by 50% when GFR <15 mL/min/1.73 m² 6
• Discontinue NSAIDs and adjust theophylline dosing if co-administration is unavoidable 1
• In geriatric patients requiring mass prophylaxis (e.g., bioterrorism scenarios), the CNS effects could lead to substantial difficulties 8

Evidence Quality Considerations

The evidence linking fluoroquinolones to seizures is predominantly low to very low quality (Class III-IV), consisting mainly of case reports and case series rather than randomized controlled trials 5. However, the consistency of reports across multiple fluoroquinolones and the biological plausibility of GABA antagonism support a real but modest association 7.

The most rigorous comparative study using propensity score matching found no statistically significant difference in seizure risk between fluoroquinolones and macrolides 2, while a self-controlled case series suggested the underlying infection may be more important than the drug itself 4.